Home › Research › TREM2 and immune genetics
Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie
Kiraly M, Foss JF, Giordano T.. The journal of prevention of Alzheimer's disease, 2023-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Neuroinflammation precedes the clinical onset of various neurodegenerative diseases, including Alzheimer's disease (AD), by years or frequently even decades (1-3). In terms of the underlying physiology, there is a great need for understanding and controlling interactions between the central nervous system (CNS) and the immune system in an attempt to develop approaches to prevent or delay the disease's progression. Nerve cells have limited motion capability, whereas immune cells can migrate freely via circulation.
What this study adds
Evidence grade: Low
This review says neuroinflammation can begin years or even decades before Alzheimer's symptoms appear, and that more must be learned about how the nervous and immune systems interact. It does not report any treatment, cure or prevention that works; it only argues that understanding these interactions is needed to try to prevent or delay progression.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kiraly, M., Foss, J. F., & Giordano, T. (2023). Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2023.109
Vancouver
Kiraly M, Foss JF, Giordano T. Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie. The journal of prevention of Alzheimer's disease. 2023. doi:10.14283/jpad.2023.109. PMID: 37874089.
BibTeX
@article{kiraly2023-37874089,
author = {Kiraly, M. and Foss, J. F. and Giordano, T.},
title = {{Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2023},
doi = {10.14283/jpad.2023.109},
pmid = {37874089},
url = {https://doi.org/10.14283/jpad.2023.109}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In terms of the underlying physiology, there is a great need for understanding and controlling interactions between the central nervous system (CNS) and the immune system in an attempt to develop approaches to prevent or delay the disease's progression.
- Nerve cells have limited motion capability, whereas immune cells can migrate freely via circulation.
- This difference raises a variety of questions in the context of senile plaque formation and phagocytosis.
- Broad-scale unbiased genomic studies bring several genetic variants such as sialic acid binding Ig-like lectin 3 (CD33), triggering receptor expressed on myeloid cells 2 (TREM2) or complement receptor type 1 (CR1) into the focus of researchers' attention as potential risk factors for neuroinflammation.
Why it matters
This review says neuroinflammation can begin years or even decades before Alzheimer's symptoms appear, and that more must be learned about how the nervous and immune systems interact. It does not report any treatment, cure or prevention that works; it only argues that understanding these interactions is needed to try to prevent or delay progression.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 38 of the 93 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 93 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 18.6 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 7.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 93 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37874089) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 38 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 38 of the 93 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.14283/jpad.2023.109
- PubMed: 37874089
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also in TREM2 and immune genetics
83 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.